Latest Kaiser Health News Stories
Ya se han vacunado unas 20 millones de personas. Sin embargo, persisten las disparidades raciales, étnicas y económicas en cuanto al acceso a las vacunas.
The number of adults seeking to get inoculated has risen since December, according to a new poll.
Nearly 6 in 10 people 65 and older say they don’t have enough information about how to get vaccinated, according to a new KFF poll.
Half the public believes the worst of the pandemic is yet to come, but most are prepared to continue to take measures to limit the spread of COVID-19 until vaccines are distributed.
Los hallazgos de una nueva encuesta indican que los votantes no confían en las garantías del presidente de que protegerá a las personas con condiciones preexistentes.
More than 50% of people said they favor Democratic presidential candidate Joe Biden’s approach to an array of health issues.
About 60% of poll respondents are worried that federal regulators will rush to allow a vaccine because of political pressure. Opposition to getting a vaccine that might be authorized before the November election is strongest among Republicans.
Of those who went without seeing a doctor or other medical provider, 11% experienced a worsened medical condition, according to the poll by the Kaiser Family Foundation. In addition, nearly 40% said stress related to the coronavirus crisis has negatively impacted their mental health.
La mayoría espera recibir atención en los próximos tres meses. Casi el 40% dijo que el estrés relacionado con el coronavirus ha afectado negativamente su salud mental.
The president, who has repeatedly pledged to improve health care and lower prescription drug prices, faces disapproval from a majority of Americans on his policies regarding drug costs, protecting people with preexisting conditions and the Affordable Care Act.
Una nueva encuesta revela que los votantes sí quieren que se hable de salud. Pero la pregunta del millón es: ¿apoyarán en las urnas un “Medicare para Todos”?.
Polls show that health care is at the top of voters’ issues, but the polls also say Democrats, let alone other Americans, are not ready for “Medicare for All.”
Washington is abuzz with impeachment talk, but what impact would such a move have on congressional action on prescription drug prices and surprise bills? Also, a study out this week shows that health insurance costs for both employers and workers continue to rise. This week, Joanne Kenen of Politico, Paige Winfield Cunningham of The Washington Post and Rebecca Adams of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more.
People at companies with large numbers of people earning $25,000 or less faced bigger deductibles for single coverage and were asked to pony up a larger share of their income in premiums than those at other firms.
Almost 80% of Americans support efforts in Congress to protect patients from bills that come from doctors or hospitals that were outside their insurance network.
Asked to choose between building on the Affordable Care Act and replacing it with a national Medicare for All plan, 55% of Democrats and Democratic-leaning independents said they would expand the existing law, according to a Kaiser Family Foundation poll released Tuesday.
On average, 16% of inpatient stays and 18% of emergency visits left a patient with at least one out-of-network charge, most of those came from doctors offering treatment at the hospital, according to a study by the Kaiser Family Foundation.
Nearly 9 in 10 Democrats or Democratic-leaning independents said it is very important for candidates to discuss health issues. But they are sharply divided among the goals of lowering costs, increasing access, protecting the Affordable Care Act or moving to a “Medicare for All” plan, a poll by the Kaiser Family Foundation reported.
Three-quarters of people urge action to keep patients from facing high medical costs when their insurance doesn’t cover the care, according to a Kaiser Family Foundation poll.
In a new poll, consumers give thumbs up to ads that display drug prices and the removal of barriers to generics, among other cost-cutting measures.